gefitinib has been researched along with Weight Loss in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arimura-Omori, M; Hamada, N; Harada, E; Ikeda-Harada, C; Mikumo, H; Nakanishi, Y; Ogata-Suetsugu, S; Suzuki, K; Yanagihara, T; Yokoyama, T | 1 |
Brink, C; Carter, CA; Chen, C; Gilbert, KS; Maxuitenko, YY; Vincent, P; Waud, WR; Zhang, X | 1 |
2 other study(ies) available for gefitinib and Weight Loss
Article | Year |
---|---|
Neutrophil elastase inhibitor sivelestat ameliorates gefitinib-naphthalene-induced acute pneumonitis in mice.
Topics: Acute Disease; Animals; Bronchoalveolar Lavage Fluid; Female; Gefitinib; Glycine; Humans; Kaplan-Meier Estimate; Leukocyte Count; Leukocyte Elastase; Lung; Mice, Inbred C57BL; Naphthalenes; Neutrophils; Pneumonia; Quinazolines; Serine Proteinase Inhibitors; Sulfonamides; Weight Loss | 2017 |
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytotoxins; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Vinblastine; Vinorelbine; Weight Loss; Xenograft Model Antitumor Assays | 2007 |